1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
MedPacto, Inc.

MedPacto, Inc.

KKRX:235980
3,055.00
KRW
-165.00
(-5.12%)
-412.32EPS
107.80BMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
113.81
145.65
Basic EPS, GAAP
-289.87
-2,420.16
-348.36
-1,066.42
-710.38
-1,455.77
-1,665
-598
-374
-412.32
Free Cash Flow per Basic Share
-231.56
-571.79
-460.89
-1,017.66
-1,086.5
-1,243.45
-1,247.83
-501.25
-398
-362.23
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-436.24
194.24
3,327.16
2,339.62
1,812.1
1,309.15
2,111.59
1,684.7
1,341.55
1,152.31
Tangible Book Value per Share
-475.1
167.69
3,301.62
2,315.92
1,788.56
1,291.4
2,101.37
1,678.04
1,324.19
1,135.21
Basic Weighted Avg Shares
12
16
39
24
24
25
21
34
34
34
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
3,898
4,995
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
-359.59
-308.64
Depreciation Expense
170
190
827
1,437
1,723
1,866
1,833
1,542
1,156
1,081
Net Income, GAAP
-3,468
-37,578
-13,516
-25,352
-17,040
-35,753
-35,325
-20,140
-12,811
-14,139
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
-328.61
-283.09
Working Capital
-3,138
27,647
74,599
46,560
125,108
27,532
67,413
55,415
43,598
37,295
LT Debt
1,462
1,597
452
159
50,706
2,423
1,687
1,480
1,126
874
Total Equity
-10,292
4,583
78,695
55,743
43,543
32,323
70,909
57,743
45,982
39,496
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
-32.46
-37.72
-34.32
-94.25
-68.44
-31.31
-24.7
-30.76

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
599
621
611
LT Borrowings
- -
- -
- -
LT Finance Leases
1,126
999
874
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
34
34
Market Capitalization
228,958
191,941
107,795

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
44,967
41,861
38,985
Cash, Cash Equivalents & STI
40,699
37,787
35,492
Accounts Receivable, Net
1,641
1,529
1,283
Inventories
646
756
340
Total Current Liabilities
1,369
1,577
1,690
Payables & Accruals
- -
- -
- -
ST Debt
599
621
611
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
6.56%
-20.37%
Free Cash Flow
- -
-8.78%
-19.25%
Net Income, GAAP
- -
-0.71%
-36.39%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
430
840
1,199
1,429
3,898
2026
1,316
1,049
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-276.31
-139
-52
-130.07
-598
2025
-100
-66
-131.87
-77.77
-374
2026
-109.7
-93
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Seong-Jin Kim
Full Time Employees
54
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Borim Building Seoul SL South Korea 06668
IPO Date
Dec 19, 2019
Website
medpacto.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
MedPacto, Inc. (KOSDAQ: 235980) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes innovative therapeutics targeting cancer and autoimmune diseases using genome-based biomarker approaches. The company offers a pipeline of small molecule drugs and antibodies, including its lead candidate vactosertib, a TGF-β signaling inhibitor indicated for solid tumors such as gastric cancer, pancreatic cancer, colorectal cancer, non-small cell lung cancer, bladder cancer and desmoid tumors; ME-1601mAb targeting BSP1 for various cancers; MS-1601A targeting TRG1 for cancers and autoimmune indications; MA-B2 antibody therapeutics; and additional biomarker-driven candidates for multiple myeloma, triple-negative breast cancer, osteosarcoma and blood cancers. MedPacto conducts operations primarily in South Korea with global clinical development collaborations and maintains U.S. and European regulatory designations including multiple FDA orphan drug approvals. Founded in 2013 and headquartered at 92 Myeongdal-ro, Seocho-gu, Seoul, the company employs approximately 61 people and listed on KOSDAQ in December 2019. In recent developments, MedPacto formed a strategic partnership with Chime Biologics in October 2024 to advance CMC process development and cGMP manufacturing for multiple preclinical candidates targeting IND submissions; completed Phase 1b/2a studies of vactosertib in combination with AstraZeneca's Imfinzi in February 2025 and Merck's Keytruda in June 2024; raised 74.1 billion KRW in capital in December 2023 to support clinical trials; secured U.S. FDA approval for a Phase 2b/3 study of vactosertib plus Keytruda in December 2023; and entered a business agreement with AI-based drug developer Hits in February 2022.